130 related articles for article (PubMed ID: 24980949)
1. EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein.
Hristodorov D; Amoury M; Mladenov R; Niesen J; Arens K; Berges N; Hein L; Di Fiore S; Pham AT; Huhn M; Helfrich W; Fischer R; Thepen T; Barth S
Mol Cancer Ther; 2014 Sep; 13(9):2194-202. PubMed ID: 24980949
[TBL] [Abstract][Full Text] [Related]
2. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
3. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
[TBL] [Abstract][Full Text] [Related]
4. Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.
Hristodorov D; Nordlohne J; Mladenov R; Huhn M; Fischer R; Thepen T; Barth S
Br J Haematol; 2014 Jan; 164(2):251-7. PubMed ID: 24164493
[TBL] [Abstract][Full Text] [Related]
5. Construction, expression, and characterization of a recombinant immunotoxin targeting EpCAM.
Lv M; Qiu F; Li T; Sun Y; Zhang C; Zhu P; Qi X; Wan J; Yang K; Zhang K
Mediators Inflamm; 2015; 2015():460264. PubMed ID: 25960617
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
7. EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer.
Subramanian N; Kanwar JR; Kanwar RK; Sreemanthula J; Biswas J; Khetan V; Krishnakumar S
PLoS One; 2015; 10(7):e0132407. PubMed ID: 26176230
[TBL] [Abstract][Full Text] [Related]
8. A Novel Immunotoxin Targeting Epithelial Cell Adhesion Molecule Using Single Domain Antibody Fused to Diphtheria Toxin.
Roshan R; Naderi S; Behdani M; Ahangari Cohan R; Kazemi-Lomedasht F
Mol Biotechnol; 2023 Apr; 65(4):637-644. PubMed ID: 36129635
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer.
Ruf P; Gires O; Jäger M; Fellinger K; Atz J; Lindhofer H
Br J Cancer; 2007 Aug; 97(3):315-21. PubMed ID: 17622246
[TBL] [Abstract][Full Text] [Related]
10. Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo.
Hristodorov D; Mladenov R; Pardo A; Pham AT; Huhn M; Fischer R; Thepen T; Barth S
Br J Cancer; 2013 Sep; 109(6):1570-8. PubMed ID: 23942071
[TBL] [Abstract][Full Text] [Related]
11. Cysteine-poor region-specific EpCAM monoclonal antibody recognizing native tumor cells with high sensitivity.
Takao M; Nagai Y; Torii T
Monoclon Antib Immunodiagn Immunother; 2013 Apr; 32(2):73-80. PubMed ID: 23607341
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1.
Vorobyeva A; Konovalova E; Xu T; Schulga A; Altai M; Garousi J; Rinne SS; Orlova A; Tolmachev V; Deyev S
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392820
[TBL] [Abstract][Full Text] [Related]
13. Anti-EpCAM scFv gadolinium chelate: a novel targeted MRI contrast agent for imaging of colorectal cancer.
Khantasup K; Saiviroonporn P; Jarussophon S; Chantima W; Dharakul T
MAGMA; 2018 Oct; 31(5):633-644. PubMed ID: 29737435
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer.
Connor JP; Felder M; Hank J; Harter J; Gan J; Gillies SD; Sondel P
J Immunother; 2004; 27(3):211-9. PubMed ID: 15076138
[TBL] [Abstract][Full Text] [Related]
15. Relationship between ganglioside expression and anti-cancer effects of the monoclonal antibody against epithelial cell adhesion molecule in colon cancer.
Kwak DH; Ryu JS; Kim CH; Ko K; Ma JY; Hwang KA; Choo YK
Exp Mol Med; 2011 Dec; 43(12):693-701. PubMed ID: 22033101
[TBL] [Abstract][Full Text] [Related]
16. Generation of an anti-EpCAM antibody and epigenetic regulation of EpCAM in colorectal cancer.
Liao MY; Kuo MY; Lu TY; Wang YP; Wu HC
Int J Oncol; 2015 Apr; 46(4):1788-800. PubMed ID: 25652097
[TBL] [Abstract][Full Text] [Related]
17. Plant-derived EpCAM antigen induces protective anti-cancer response.
Brodzik R; Spitsin S; Golovkin M; Bandurska K; Portocarrero C; Okulicz M; Steplewski Z; Koprowski H
Cancer Immunol Immunother; 2008 Mar; 57(3):317-23. PubMed ID: 17634938
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution studies of epithelial cell adhesion molecule (EpCAM)-directed monoclonal antibodies in the EpCAM-transgenic mouse tumor model.
Kosterink JG; McLaughlin PM; Lub-de Hooge MN; Hendrikse HH; van Zanten J; van Garderen E; Harmsen MC; de Leij LF
J Immunol; 2007 Jul; 179(2):1362-8. PubMed ID: 17617629
[TBL] [Abstract][Full Text] [Related]
19. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
20. An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.
Liao MY; Lai JK; Kuo MY; Lu RM; Lin CW; Cheng PC; Liang KH; Wu HC
Oncotarget; 2015 Sep; 6(28):24947-68. PubMed ID: 26317650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
